- Home
- FLGC vs CLDI Comparison
FLGC vs CLDI Comparison
Compare FLGC & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- CLDI
- Stock Information
- Founded
- FLGC 2019
- CLDI 2014
- Country
- FLGC United States
- CLDI United States
- Employees
- FLGC N/A
- CLDI N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLGC Health Care
- CLDI Health Care
- Exchange
- FLGC Nasdaq
- CLDI Nasdaq
- Market Cap
- FLGC 15.9M
- CLDI 10.2M
- IPO Year
- FLGC 2021
- CLDI N/A
- Fundamental
- Price
- FLGC $0.62
- CLDI $0.23
- Analyst Decision
- FLGC Buy
- CLDI Strong Buy
- Analyst Count
- FLGC 2
- CLDI 1
- Target Price
- FLGC $4.00
- CLDI $10.00
- AVG Volume (30 Days)
- FLGC 111.0K
- CLDI 1.8M
- Earning Date
- FLGC 08-11-2025
- CLDI 08-12-2025
- Dividend Yield
- FLGC N/A
- CLDI N/A
- EPS Growth
- FLGC N/A
- CLDI N/A
- EPS
- FLGC N/A
- CLDI N/A
- Revenue
- FLGC $53,260,000.00
- CLDI N/A
- Revenue This Year
- FLGC N/A
- CLDI N/A
- Revenue Next Year
- FLGC N/A
- CLDI N/A
- P/E Ratio
- FLGC N/A
- CLDI N/A
- Revenue Growth
- FLGC N/A
- CLDI N/A
- 52 Week Low
- FLGC $0.42
- CLDI $0.20
- 52 Week High
- FLGC $2.11
- CLDI $3.89
- Technical
- Relative Strength Index (RSI)
- FLGC 42.89
- CLDI 23.09
- Support Level
- FLGC $0.62
- CLDI $0.20
- Resistance Level
- FLGC $0.72
- CLDI $0.25
- Average True Range (ATR)
- FLGC 0.06
- CLDI 0.04
- MACD
- FLGC -0.01
- CLDI -0.01
- Stochastic Oscillator
- FLGC 14.79
- CLDI 17.07
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.